Senti Biosciences, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Senti Biosciences, Inc. is a biotechnology company specializing in the design and engineering of synthetic biological circuits aimed at developing programmable cell therapies and precision medicines. Its core products and services include synthetic biology platforms for creating next-generation therapeutics such as engineered immune cells, gene circuits, and modular biological systems. The company focuses on programmable cell therapy solutions targeting cancer, autoimmune diseases, and other serious conditions. Senti Biosciences operates primarily in the United States with research and development headquartered in South San Francisco, California. Founded in 2017, the company combines proprietary synthetic biology tools and clinical development expertise to advance its pipeline of cell-based therapies. Recently, Senti Biosciences has been active in strategic partnerships and expansions to accelerate its therapeutic pipeline. In 2024-2025, the company announced key collaborations with leading pharmaceutical and biotech firms to co-develop novel cell therapies leveraging synthetic gene circuits. It also secured new funding rounds to advance clinical trials and expand its R&D capabilities. The company has introduced new product offerings focused on modular therapeutic platforms that enable fine control over cellular behavior in treatment contexts. These developments mark a strategic evolution toward broader applications of programmable cell therapies beyond oncology, including autoimmune and infectious diseases. Senti Biosciences continues to grow its operational footprint while maintaining a focus on innovation in synthetic biology and cell therapy modalities. The company serves diverse customer segments in the biotechnology and pharmaceutical industries, including research institutions, healthcare providers, and biopharma partners. Its business segments span synthetic biology tools, therapeutic development, and collaborative research services. Senti Biosciences positions itself at the forefront of precision medicine by integrating cutting-edge synthetic biology with clinical applications. It remains a private entity with a strong emphasis on innovation-driven growth, supported by its expertise in gene editing, bioengineering, and translational medicine. This comprehensive profile highlights Senti Biosciences, Inc. as a pioneering synthetic biology company founded in 2017, headquartered in South San Francisco, California, offering programmable cell therapy products and services with recent expansions through partnerships, funding, and novel product launches within the last two years.
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Senti Biosciences Announces New Employment Inducement Grants
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET